LIPOSOMAL TRANSFECTION METHOD

Abstract: An improvement in a method for transfecting a cell with a nucleic acid, the improvement comprising contacting the cell with a liposomal transfection composition comprising: the nucleic acid; sphingosine or a derivative thereof, having a protonable amino group in the sphingosine moiety; and at least one helper lipid.

Description: LIPOSOMAL TRANSFECTION METHOD FIELD OF INVENTION The present invention relates to a method of transfecting a ceil with nucleic acid, such as DNA, using, as the transfection vector, a liposomal composition comprising a sphingosine derivative having a protonated amino group in the sphingosine moiety. The protonated ammo group provides for the required cationic nature of the liposome for forming a complex with the negatively charged nucleic acid. According to the in¬ vention it was shown that the sphingosine containing liposomal composi¬ tion, which had been pre-incubated with nucleic acid, such as DNA, transfected efficiently the cell lines tested . BACKGROUND OF THE INVENTION Liposomes are widely used for drug delivery and for delivery of foreign DNA to mammalian cells, and they offer several advantages in this re¬ spect. Such advantages are ease of manufacture, commercial availability, the possibility of targeting to specific cells or tissues, and high transfec¬ tion efficiency. Cationic liposomes, that is liposomes comprising at least some positively charged lipids to give an overall positive charge to the li¬ posomes, have been used for gene transfer, i.e. transfection of DNA, into mammalian cells both in vivo and in vitro. Due to charge interac- tions, the positively charged liposome forms easily, in a simple mixing process, on its surface a complex with the negatively charged DNA. The complex in turn binds strongly to the cell surface due to favorable charge interactions followed by internalization of the complex into the cell and expression of the gene (Singhal, A. and Huang, L ( 1994) Gene Thera- peutics (ed.: Wolff, J.A.) pp 1 1 8-142, Birkhauser, Boston) Various cationic lipids have been suggested in the art for incorporation into liposomes, including quaternary ammonium detergents, e g cetyltπ- methylammonium bromide (CTAB), cationic derivatives of cholesterol and diacyi glycerol, e.g. 1 ,2-dioleyl-3-(4'-trimethylammonio)butanoyl-sn-gly- cerol (DOTB), and lipopolyamines, e.g. lipopoly-L-lysine (LPLL). Also commercial preparations are available. Lipofectin ',, is a widely used com- mercial preparation comprising N-[1 -(2,3-dioleyloxy)propyl]-N,N,N-trimet- hylammonium chloride (DOT A) in combination with dioleoylphosphati- dylethanolamine (DOPE) (Gibco). The apparent toxicity of some of the commercially available products have been referred to the non-natural, non-biodegradable nature of compounds contained by them (Singhal et al., ibid). The cationic liposomes used as a transfection vector commonly contain, in addition to the cationic lipid, a neutral or negatively charged lipid, so called helper lipid or co-lipid, the above mentioned DOPE being one such neutral helper lipid. Also other helper lipids have been suggested. Such helper lipids are typically phospholipids, and besides DOPE, e.g. dio- leoylphosphatidylcholine (DOPC), dioleoylphatidylserine (DOPS), the cor¬ responding dilauroyl, dimyristoyl and dipalmitoyl compounds, phospha- tidic acid, phosphatidylglycerol, sterols, such as cholesterol, and mixtu- res of these have been suggested. The mono-, di- and triglycerides may be mentioned as further neutral helper lipids. A main function of the helper lipid is to fuse into and stabilize the liposome bilayer structure. It is also known that DOPE, in addition to the liposomal stabilizing effect, aids in the cytoplasmic delivery of DNA in the cell. A wide variety of patent literature is available disclosing various cationic lipids for use for transfection, see e.g. US 5,264,61 8, WO 93/03709, and WO 95/1 7373, just to mention a few. Although a number of advantages are obtained by using cationic li¬ posomes as carriers for DNA, rather than neutral or anionic liposomes, many problems still remain both in in vivo and in vitro applications. A major problem with many of the cationic lipids is that they are generally - toxic to the cells, and thus of limited use. This is especially true of Lipo¬ fectin * , the DOTMA component of which is a diether, and not readily degraded in vivo and toxic to tissue cells. Thus DOTMA is not optimal from the point of view of in vivo gene delivery. According to the invention it has now been discovered that by using a specific group of cationic lipids for inclusion into the transfection vector, it is possible to provide a method of transfection displaying clearly impro- ved transfection efficiencies with minimal toxicity problems to the trans¬ fected cells. SUMMARY OF THE INVENTION The object of the present invention is thus a method for transfecting a cell with a nucleic acid which comprises contacting the cell with a li¬ posomal transfection composition comprising - a nucleic acid, - sphingosine or a derivative thereof, having a protonated amino group in the sphingosine moiety, and - a helper lipid. DETAILED DESCRIPTION OF THE INVENTION Sphingosine derivatives are amphiphilic lipids, i.e. they comprise an ami¬ no alcohol substituted with a single fatty chain. Several sphingosine derivatives occur naturally in mammalian and non-mammalian cells, and they can be degraded in connection with normal cellular metabolism. The role of sphingosines in influencing DNA synthesis and gene expressi- on is, however, largely unknown. It is also known that sphingosine and some of its cationic derivatives in liposomal form bind strongly to DNA (Koiv, A. and Kinnunen, P.K.J . , Chem. Phys. Lipids, 72 ( 1 994) 77-86). Another feature of the sphingosine is its ability to inhibit the protein kinase C (PKC). The inhibition of PKC has been proposed to be a critical factor determining the transfection efficiency and toxicity of a given liposome vector (Singhal et al., ibid. p. 125). Sphingosine containing li- posomes have not been suggested for use in transfection vectors, appa¬ rently due to the fact that sphingosine, being a PKC inhibitor, would be expected to resist transfection. According to the invention it has now, however, been discovered that this is not the case, and that substantially enhanced transfection efficiencies, without appended toxicity to the cells, can be obtained, as compared to using Lipofectin * , by including, in the liposome vector, at least one positively charged sphingosine derivati¬ ve. The main criteria when choosing the sphingosine derivative to be used according to the invention is that the amino group in the sphingosine moiety is in protonable form, in order to provide for the necessary overall cationic nature to the liposome vector formed by the sphingosine com¬ pound and the helper lipid . The cationic nature of the liposome in turn is critical for the efficient binding of the negatively charged nucleic acid to the surface of the liposome. Especially contemplated for use in the inven¬ tion are the sphingosine derivatives having the following general formula wherein X and Y are each, independently of each other, H or OH, or together form a double bond, R is H or phosphorylcholine -PO( = 0)(-O )(CH 2 ) 2 N + (CH 3 ) 3 R, and R 2 are independently H or a lower alkyl group. A lower alkyl group as R, and/or R 2 is preferably one with 1 -3 carbon atoms, preferably methyl. X is preferably H or forms a double bond with Y. Especially contemplated for use in the invention are the sphingosine deri¬ vatives of the above formula selected from the group consisting of sphin¬ gosine, phytosphingosine, dihydrosphingosine and dimethylsphingosine. According to the invention, the liposomal transfection vector includes also at least one helper lipid, which is not a sphingosine derivative. Such a lipid is typically selected from the group of neutral phospholipids, typi¬ cally it is phosphatidylethanolamine, or a diacyiglycerol. The helper lipid has fusogenic properties meaning that the lipid has the property of facili- tating the fusion of lipid membranes, see e.g. Kinnunen, P. K. J., Chem. Phys. Lipids. , 63 (1992)251-258. However, within the context of the invention, any lipid which has fusogenic properties and which is neutral or which does not substantially alter the cationic nature of the formed li¬ posome, can come into question. According to a preferred embodiment of the invention the composition comprises a first helper lipid which is selected from fusogenic neutral phospholipids, especially from phosphatidylethanolamines, and a second helper lipid selected from diacyl glycerols. A preferred phospholipid is phosphatidylethanolamine, especially dioleo- ylphosphatidylethanolamine (DOPE), or the corresponding dilauroyl, dimyristoyl and dipalmitoyl compounds. A preferred liposome composi¬ tion of the invention contains from 10 to 90 % by weight of helper lipid, such as phospholipid, in combination with 10 to 90 % by weight of a sphingosine derivative. A more preferred composition is from 30 to 70 % by weight of helper lipid and 70 to 30 % by weight of a sphingosine derivative. As will be shown later, very good results have been obtained using DOPE and sphingosine in an amount of 1 : 1 (wt:wt), which corres ponds to a molar ratio between the compounds of appr. 1 :2. According to a preferred embodiment of the invention, the cationic li¬ posomal composition includes a glyceride, preferably a diacyl glycerol as a second helper lipid. According to the invention it has namely been shown that the transfection efficiency in terms of expression can be increased by incorporating an amount of diacyl glycerol in the composi- tion. For the purpose of the invention, especially a diacyl glycerol selec¬ ted from dioleoylglycerol and dioctanoylglycerol, are contemplated . Dia ¬ cyl glycerol, when mcluded as a second helper lipid, is included in an amount of up to 25 mole % calculated from the lipid composition of the liposome. Optimal results have been obtained using appr. 5 to 1 0 mole % of such diacyl glycerols (calculated of total lipids). The preparation of the liposomes to be used according to the invention is well known to a person skilled in the art, see for example Kinnunen P. K. J , et al., Chem. Phys. Lipids 66 ( 1993) 75-85, describing the preparati- on of multilamellar liposomes. Briefly, sphingosine and any further lipids to be used are mixed in a suitable solvent, e.g. in chloroform, and evapo¬ rated to dryness under a stream of nitrogen. To prepare the liposomes, the thus dried lipid mixture is hydrated in a buffer, including short pe¬ riodical vortexing, and sonicated at the end of the hydration period, to form multilamellar liposomes. Nucleic acid includes in this context DNA and RNA, and oligonucleotides of DNA and RNA. To prepare the nucleic acid-lipid complex, the nucleic acid and the lipids are each diluted in an appropriate medium, for example in serum free DMEM (Dulbecco's Modified Eagle's Medium), mixed and preincubated for a suitable period of time. The amount of nucleic acid to lipid can vary, but a weight ratio between nucleic acid and lipid in the range of 0 25: 1 5 to 4:5 has been found to be satisfactory. Due to charge interactions, the nucleic acid forms a strong complex with the cationic liposome surface after simple mixing of the components. Good transfection results have been obtained in tests using 1 or 2 μg respectively of DNA to 10 μg of total pid. The concentration of nucleic acid in the transfection medium is suitably adjusted to 1 to 2 μg/ml. The term "cell" means in this context an animal cell or a plant cell Uni¬ cellular organisms as well as multicellular organisms or systems such as cell cultures are contemplated in the invention Methods of transfection are well known in the art and such known met- hods can be used with the present liposome compositions as well The invention thus concerns an improved method of transfection, the impro¬ vement comprising using, as the transfection vector, a liposome comp¬ rising a nucleic acid and a sphingosine derivative, and preferably a helper phospholipid The invention will be described in more detail in the following examples, referring to enclosed drawing, wherein Figure 1 shows the effect of different liposomal combinations on the transfection efficiency of pCMV-luci in KK-1 cells KK-1 cells were trans¬ fected with 10 μg lipid and 1 μg CMV-luci plasmid After harvest, the luciferase activity of the cell lysates were measured Buff = cells not transfected; 0 = cells transfected with 1 μg DNA only, with no li posomes; sph-PC = sphingosylphosphorylcholme; sph = sphingosine; phsph = phytosphingosine; DE = DOPE; DG = DOG, DOPE and sphingo¬ sine were mixed 1 : 1 (wt:wt) and 10 mole % of DOG was added were indicated Figure 2 shows the transfection efficiency of DOPE-phytosphingosine liposomes added with 5 mole % of either dioctanoylglycerol (DOcG) or dioleoylglycerol (DOG) and tested on HeLa and KK-1 cells. 10 μg of lipid and 2 μg (HeLa cells) or 1 μg (KK-1 cells) of DNA was used in the trans- fection. The expression was compared to that in the cells transfected with Lipofectin * . Figure 3a shows the effect of adding different molar percentages of DOG into DOPE-phytosphingosine liposomes. 10 μg of total lipid and 1 μg of DNA was used to transfect KK-1 cells. Figure 3b shows the effect of combining different molar percentages of DOcG into DOPE-phytosphingosine liposomes. 10 μg of total lipid and 1 μg of DNA was used to transfect KK-1 cells. Figure 4 shows the transfection efficiency using various DNA/total lipid ratios on KK-1 cells. The liposome composition was DOPE:phy- tosphingosine in a ratio of 1 : 1 (wt:wt) and 5 mol% of DOG . Figure 5 shows the results of storage tests of liposomes carried out on KK- 1 cells. The dark column represents storage for a composition accor¬ ding to the invention (composition as in Figure 4 except that DOcG was used instead of DOG) stored at + 4 °C and the grey column that of the same composition stored at -20 °C. The striped column represents stora- ge results for Lipofectin " stored at + 4 °C according to the instructions of the manufacturer. EXAMPLES Preparation of a transfection liposome Liposomes were prepared using lipid stocks of DOPE and of appropriate sphingosine derivative selected from sphingosine, phytosphingosine and phosphorylcholine-sphingosine. The lipids chosen were dissolved in chlo¬ roform at a ratio of 1 : 1 (by weight). To the solution obtained either di¬ oleoylglycerol (DOG) or dioctanoylglycerol (DOcG) were added in indica- ted amounts, up to 30 mole %. The solvent was evaporated under a stream of nitrogen and the drying was continued in a lyophilizator for at least 2 hours or overnight. Thereafter the dry lipid mixture was hydrated in a buffer containing 20 mM Hepes, 150 mM NaCl, 0.1 EDTA, pH 7.4, for 30 minutes at 40°C in a water bath, and vortexed briefly every 5 minutes. At the end of hydration the liposomes obtained were sonicated for appr. 5 minutes. The total lipid concentration of the liposomes was usually 100 μg/ml buffer. The liposomes prepared were kept in a refri¬ gerator, in closed test tubes. Lipofectin * was used as the reference liposome vector according to the instructions of the manufacturer. Preparation of DNA-lipid complexes The pCMV-luciferase construct used in the experiments was designed to carry the promoter area of the cytomegalo virus in front of the firefly luciferase coding sequence in an expression vector PUHC1 3-1 (Gossen M., and Bujard H., Proc. Natl. Acad. Sci. 89 ( 1992), 5547-5551 ) . The DNA preparation was purified twice with CsCl gradient centrifugation and dissolved in sterile water for the transfections. The identity of the CMV-luciferase construct was verified using the specific restriction en¬ donuclease digestion. DNA and the lipid were each diluted to 100 μl of serum free DMEM (DMEM-SF) and then mixed. 1 μg or 2 μg, respectively, of DNA and 10 μg of total lipid were pre-incubated for 15 minutes. Thereafter the total volume of the mixture was adjusted to 1 ml with DMEM-SF. The DNA- pid complexes formed rapidly after mixing and had a stable transfectabi- lity at least for one hour at the concentration used . Transfection As cell cultures the cell line KK-1 and HeLa cells were used.The KK-1 cells were derived from transgenic murine ovarian tumour cells immortali¬ zed by expression of the simian virus 40 large and small tumour (T) anti gens under the control of inhibin-σ subunit promoter (Kananen K , et al Mol. Endocrinol. 9 ( 1995) 61 6-627) . The HeLa cells are derived from human uterine cervix carcinoma (see e.g. Gossen, M. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 5547-5551 ). The cells were grown on plastic tissue culture plates in Dulbecco's modified Eagle's medium with 10 % fetal bovine serum (DMEM-10) in an incubator in an atmosphere of 5 % At least 80 % confluent six-well cell culture plates were washed with DMEM-SF and the DNA-lipid complexes were laid over the cells For each well 1 μg DNA/10 μg liposome was used for KK-1 cells and 2 μg/10 μg liposomes for HeLa cells. For each test, 2-3 parallel wells were used After a 10 hour incubation period at 37°C, the DNA-lipid mixture was replaced by 2 ml of DMEM-10. Three days after beginning of transfecti on, the cells were harvested by scraping off the culture plates The cell extracts were prepared and a luminometπc assay for luciferase activity was performed by measuring the activity of the protein (the ATP lucifera- se enzyme) produced by the cells, by measuring the degradation of ATP by the luciferase enzyme (see e.g. Gould S., et al., Anal. Biochem. 1 ( 1988), 5-13; Nguyen V., Anal. Biochem 1 71 (1 988) 404-408 In brief, 50 μl of the total of 100 μl of the cell extracts were mixed with 360 μl of assay buffer by short vortexing in a disposable cuvette. The cuvettes were thereafter placed in a Bio-Orbit Luminometer 1252 (Bio-Orbit Ltd., Turku, Finland) and the luminesence was measured after adding 200 μl of luciferin solution. When the luciferase activity of a sample was excee¬ ding the measuring range, a smaller amount (10 or 20 μl) of the cell extract was used at re-measurement. In order to measure PKC stimulation, phorbol mynstic acid (PMA) (1 % of moles of lipids) was added to the liposome solutions. Transfection and expression analysis were performed as described above. Results As is evident from the Fig. 1 , the phytosphingosine and sphingosine containing liposomes showed major transfection efficiency in KK-1 cells comparable to or exceeding that of Lipofectin * . The transfection efficien¬ cy is poor in compositions not containing DOPE The transfection effi¬ ciency in HeLa cells was somewhat poorer than that in KK-1 cells, see Fig 2. After incubation of KK-1 cells with liposomes for 1 6 h or longer, the cells transfected with Lipofectin" had almost all died, whereas the sphingosine liposomes showed no marked cell death The HeLa cells tolerated better Lipofectin * showing less damage after incubation periods over 10 hours Adding diacylglycerol to the shingosine lipid composition affected the transient luciferase expression in a biphasical dose dependant manner (Fig. 3). From the results it is evident that dioleoylglycerol doubled the transfection at the optimal 5 % molar concentration, and that dioctanoyl glycerol was most efficient at 5 to 10 % molar concentrations Concent¬ rations higher than appr. 25 molar % gave no improvement but rather caused lower expression. In wells stimulated by PMA, the expression was only a fourth of those not stimulated. The results shown in Fig. 4 show that the DNA/lipid ratio is not very critical and that ranges from 0.25μg/1 5μg to 4μg/5μg gave satisfactory results. The storage test results of Fig. 5 indicate that the compositions for use according to the invention have at least comparable storage cha¬ racteristics as compared to Lipofectin * . The results show that the toxicity of the sphingosine derivative con¬ taining liposomes on cells, such as KK-1 cells, apparently is lower than that of the widely used transfection liposomal preparation Lipofectin 1 It is contemplated that the non-biodegradabale DOTMA included in Lipofec¬ tin * may account for the difference. Thus especially sensitive cell lines could more easily be handled with less toxic vectors. Some special cellu lar functions may also be disturbed in dying cells, e.g. promoter function experiments might be aberrated due to toxic effects The PKC activators can increase the transfection efficiency by the calcium phosphate met¬ hod (Reston J., et al., Biochem. Biophys. Acta 1088 (1991 ), 270-276) According to the invention, however, adding PMA to the liposome soluti¬ on lowered the expression of the luciferase gene The PKC activity thus seems to affect the sphingohpid liposome mediated transfection in oppo site fashion, as compared with calcium phosphate transfection. The availability and low cost of the components used according to the invention is a well acknowledged benefit in practice The liposomes are easily prepared and the time consumption is modest Hence the sphin gosine derivative based liposomes are an efficient, low toxicity alternati ve for DNA transfection to cells in vitro. They may be of use also in transfection of other materials and in in vivo transfection

Claims: Claims 1 . An improvement in a method for transfecting a cell with a nucleic acid the improvement comprising contacting the cell with a liposomal transfection composition comprising - the nucleic acid, - sphingosine or a derivative thereof, having a protonable amino group in the sphingosine moiety, and - a helper lipid. 2. The improvement according to the claim 1 , wherein the helper lipid is a neutral phospholipid . 3. The improvement according to the claim 2, wherein the phospholipid is a phosphatidylethanolamine. 4. The improvement according to the claim 2, wherein the composition comprises a diacyl glycerol as a further helper lipid. 5. The improvement according to the claim 1 , wherein the sphingosine derivative is a compound of the formula wherein X and Y are each, independently of each other, H or OH, or together form a double bond, R is H or phosphorylcholine -PO( = 0)(-0 ) (CH 2 ) 2 N + (CH 3 ) 3 R-i and R 2 are independently H or a lower alkyl group. 6. The improvement according to the claim 5, wherein the sphingosine derivative is selected from the group consisting of sphingosine, phy- tosphingosine, dihydrosphingosine and dimethylsphingosine. 7. The improvement according to the claim 2, wherein the phospholipid is dioleoylphosphatidylethanolamine (DOPE). 8. The improvement according to the claim 2, wherein the phospholipid is a phosphatidylethanolamine and the composition comprises a further- helper lipid selected from the group consisting of dioleoyl- or dioctanoyl- glycerol. 9. The improvement according to the claim 2, wherein the composition further comprises a compound selected from cholesterol and sterol, and their derivatives. 10. The improvement according to the claim 1 , wherein the composition comprises dioleoylphosphatidylethanolamine and a diacylglycerol selected from dioleoylglycerol and dioctanoylglycerol. 1 1 . The improvement according to the claim 1 or 2, wherein the compo¬ sition contains sphingosine or a derivative thereof in an amount of 10 to 90 % by weight and a helper lipid in an amount from 10 to 90 % by weight, calculated from the combined weight of sphingosine or its deπ- vative, and helper pid. 1 2. The improvement according to the claim 1 or 2, wherein the compo¬ sition contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and helper lipid in an amount of from 30 to 70 % by weight, calculated from the combined weight of sphingosine or its deri¬ vative, and helper lipid. 1 3 The improvement according to the claim 1 or 2, wherein the ratio between sphingosine or a derivative thereof and the helper lipid is appr 1 1 (wt/wt). 14 The improvement according to the claim 2, wherein the composition contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and phospholipid in an amount of from 30 to 70 % by weight, calculated from the combined weight of sphingosine or its derivative and of phopshohpid, and a diacyl glycerol as a further helper lipid in an amount of up to 25 mole-% calculated on the total amount of lipids 1 5 The improvement according to the claim 2, wherein the composition contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and phospholipid in an amount of from 30 to 70 % by weight, calculated from the combined weight of sphingosine or its derivative and of phopshohpid, and a diacyl glycerol as a further helper pid in an amount of 5 to 10 mole-% of a diacylglycerol, calculated on the total amount of lipids 1 6 The improvement according to the claim 1 , wherein the ratio bet ween nucleic acid and total lipids is 0.25 1 5 to 4 5 (wt/wt) 1 7 The improvement according to the claim 1 , wherein the hpid compo sition comprises 30 to 70 % by weight of a compound selected from sphingosine and phytosphmgosine 30 to 70 % by weight of dioleoylphosphatidylethanolamine, the said %'s by weight being calculated on the combined weight of sphin gosine and phosphatidylethanolamine compounds, and in addition 5 to 1 5 mole %, calculated from the amount of total hpids, of a compound selected from dioleoylglycerol and dioctanoylglycerol AMENDED CLAIMS [received by the International Bureau on 18 Apri l 1997 ( 18.04.97) ; original claims 1 -17 repl aced by amended claims 1 -16 (3 pages)] 1 An improvement in a method for transfecting a cell with a nucleic acid the improvement comprising contacting the cell with a liposomal transfection composition comprising - the nucleic acid, - sphingosine or a derivative thereof, having a protonable amino group in the sphingosine moiety, and of the formula wherein X and Y are each, independently of each other, H or OH, or together form a double bond, R is H, R, and R 2 are independently H or a lower alkyl group, and - a helper lipid 2 The improvement according to the claim 1 , wherein the helper pid is a neutral phospholipid 3 The improvement according to the claim 2, wherein the phospholipid is a phosphatidylethanolamine 4 The improvement according to the claim 2, wherein the composition comprises a diacyl glycerol as a further helper lipid 5 The improvement according to the claim 1 , wherein the sphingosine deri¬ vative is selected from the group consisting of sphingosine, phytosphingosi- ne, dihydrosphingosine and dimethylsphingosine 6 The improvement according to the claim 2, wherein the phospholipid is dioleoytphosphatidylethanolamine (DOPE) 7 The improvement according to the claim 2, wherein the phospholipid is a phosphatidylethanolamine and the composition comprises a further helper hpid selected from the group consisting of dioleoyl- or dioctanoylglycerol 8 The improvement according to the claim 2, wherein the composition furt¬ her comprises a compound selected from cholesterol and sterol, and their derivatives 9 The improvement according to the claim 1 , wherein the composition comprises dioleoylphosphatidylethanolamine and a diacylglycerol selected from dioleoylglycerol and dioctanoylglycerol 10 The improvement according to the claim 1 or 2, wherein the composi¬ tion contains sphingosine or a derivative thereof in an amount of 10 to 90 % by weight and a helper hpid in an amount from 10 to 90 % by weight, calculated from the combined weight of sphingosine or its derivative, and helper lipid 11 The improvement according to the claim 1 or 2, wherein the composi¬ tion contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and helper lipid in an amount of from 30 to 70 % by weight, cal¬ culated from the combined weight of sphingosine or its derivative, and hel¬ per lipid 12 The improvement according to the claim 1 or 2, wherein the ratio bet¬ ween sphingosine or a derivative thereof and the helper pid is appr 1 1 (wt wt) 13 The improvement according to the claim 2, wherein the composition contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and phospholipid in an amount of from 30 to 70 % by weight, calcu¬ lated from the combined weight of sphingosine or its derivative and phospholipid, and a diacyl glycerol as a further helper hpid in an amount of up to 25 mole-% calculated on the total amount of lipids 14 The improvement according to the claim 2, wherein the composition contains sphingosine or a derivative thereof in an amount of 30 to 70 % by weight and phospholipid in an amount of from 30 to 70 % by weight, calcu¬ lated from the combined weight of sphingosine or its derivative, and phospholipid, and a diacyl glycerol as a further helper hpid in an amount of 5 to 10 mole-% of a diacylglycerol, calculated on the total amount of lipids 15 The improvement according to the claim 1 , wherein the ratio between nucleic acid and totai lipids is 0 25 15 to 4 5 (wt wt) 16 The improvement according to the claim 1 , wherein the hpid composi¬ tion comprises - 30 to 70 % by weight of a compound selected from sphingosine and phytosphingosine - 30 to 70 % by weight of dioleoylphosphatidylethanolamine, the said % by weight being calculated on the combined weight of sphingosine and phosphatidylethanolamine compounds, and in addition - 5 to 15 mole %, calculated from the amount of total lipids, of a com¬ pound selected from dioleoylglycerol and dioctanoylglycerol

Inventors: HUHTANIEMI ILPO, KINNUNEN PAAVO, LAURAEUS SATU, PAUKKU TOMMI, HUHTANIEMI, ILPO, KINNUNEN, PAAVO, LAURAEUS, SATU, PAUKKU, TOMMI
Applicants: HUHTANIEMI ILPO, KINNUNEN PAAVO, LAURAEUS SATU, PAUKKU TOMMI, HUHTANIEMI, ILPO, KINNUNEN, PAAVO, LAURAEUS, SATU, PAUKKU, TOMMI
Application year: 1996
Main classification: C12N15
IPC codes: A61K9, C07F9, C12N15